Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

NCT03820596 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Safety and Efficacy

Interventions

DRUG: Sintilimab
DRUG: Chidamide

Sponsor

Huiqiang Huang